Hypoxia and Myocardial Remodeling in Human Cardiac Allografts: A Time-course Study

Journal of Heart and Lung Transplantation

Volumn 28, Issue 11, 2009, Pages 1119-1126

  Gramley, Felix ^a   Lorenzen, Johann ^b   Pezzella, Francesco ^c   Kettering, Klaus ^a   Himmrich, Ewald ^a   Plumhans, Cedric ^d   Koellensperger, Eva ^e   Munzel, Thomas ^a  

^a JOHANNES GUTENBERG UNIVERSITY   (Germany)

^b Dortmund Hospital   (Germany)

^c UNIVERSITY OF OXFORD   (United Kingdom)

^d RWTH AACHEN UNIVERSITY   (Germany)

^e UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CYCLOSPORIN A; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; HYPOXIA INDUCIBLE FACTOR 1ALPHA; OXYGENASE; PREDNISONE; PROLYL HYDROXYLASE 3; UNCLASSIFIED DRUG; VASCULOTROPIN;

ADULT; ARTICLE; ATHEROSCLEROTIC CARDIOVASCULAR DISEASE; CARDIAC GRAFT REJECTION; CARDIOMYOPATHY; CELL LOSS; CONGESTIVE CARDIOMYOPATHY; DNA CONTENT; DRUG DOSE REDUCTION; FEMALE; FIBROGENESIS; FIBROSING ALVEOLITIS; FOLLOW UP; HEART MUSCLE BIOPSY; HEART MUSCLE CELL; HEART MUSCLE FIBROSIS; HEART MUSCLE ISCHEMIA; HEART RIGHT VENTRICLE; HEART TRANSPLANTATION; HEART VENTRICLE REMODELING; HUMAN; HUMAN TISSUE; HYPERTENSION; HYPOXIA; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; MORPHOMETRICS; ORGAN DONOR; OXYGEN SENSING; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ANOXIA; ENDOMYOCARDIAL FIBROSIS; FEMALE; FOLLOW-UP STUDIES; HEART DISEASES; HEART TRANSPLANTATION; HEART VENTRICLES; HUMANS; HYPERTENSION; MALE; MIDDLE AGED; TIME FACTORS; TRANSPLANTATION, HOMOLOGOUS; VENTRICULAR REMODELING;

EID: 70350054596     PISSN: 10532498     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.healun.2009.05.038     Document Type: Article

References (39)

1. Armstrong A.T., Binkley P.F., Baker P.B., et al. Quantitative investigation of cardiomyocyte hypertrophy and myocardial fibrosis over 6 years after cardiac transplantation. J Am Coll Cardiol 32 (1998) 704-710
2. Johnson D.W., Saunders H.J., Johnson F.J., et al. Cyclosporin exerts a direct fibrogenic effect on human tubulointerstitial cells: roles of insulin-like growth factor I, transforming growth factor beta1, and platelet-derived growth factor. J Pharmacol Exp Ther 289 (1999) 535-542
3. Ozdemir B.H., Ozdemir F.N., Demirhan B., et al. TGF-beta1 expression in renal allograft rejection and cyclosporine A toxicity. Transplantation 80 (2005) 1681-1685
4. Ozdemir B.H., Ozdemir F.N., Haberal N., et al. Vascular endothelial growth factor expression and cyclosporine toxicity in renal allograft rejection. Am J Transplant 5 (2005) 766-774
5. Burdmann E.A., Andoh T.F., Nast C.C., et al. Prevention of experimental cyclosporin-induced interstitial fibrosis by losartan and enalapril. Am J Physiol 269 (1995) F491-F499
6. Pickering J.G., and Boughner D.R. Fibrosis in the transplanted heart and its relation to donor ischemic time. Assessment with polarized light microscopy and digital image analysis. Circulation 81 (1990) 949-958
7. Yamani M.H., Haji S.A., Starling R.C., et al. Myocardial ischemic-fibrotic injury after human heart transplantation is associated with increased progression of vasculopathy, decreased cellular rejection and poor long-term outcome. J Am Coll Cardiol 39 (2002) 970-977
8. Gramley F., Lorenzen J., Jedamzik B., et al. Atrial fibrillation is associated with cardiac hypoxia. Cardiovasc Pathol (2009 Feb 10) [Epub ahead of print]
9. Sinno H., Derakhchan K., Libersan D., et al. Atrial ischemia promotes atrial fibrillation in dogs. Circulation 107 (2003) 1930-1936
10. De Boer R.A., Pinto Y.M., and Van Veldhuisen D.J. The imbalance between oxygen demand and supply as a potential mechanism in the pathophysiology of heart failure: the role of microvascular growth and abnormalities. Microcirculation 10 (2003) 113-126
11. Harris A.L. Hypoxia-a key regulatory factor in tumour growth. Nat Rev Cancer 2 (2002) 38-47
12. Epstein A.C., Gleadle J.M., McNeill L.A., et al. C. elegans EGL-9 and mammalian homologs define a family of dioxygenases that regulate HIF by prolyl hydroxylation. Cell 107 (2001) 43-54
13. Stewart S., Winters G.L., Fishbein M.C., et al. Revision of the 1990 working formulation for the standardization of nomenclature in the diagnosis of heart rejection. J Heart Lung Transplant 24 (2005) 1710-1720
14. McGiffin D.C., Savunen T., Kirklin J.K., et al. Cardiac transplant coronary artery disease. A multivariable analysis of pretransplantation risk factors for disease development and morbid events. J Thorac Cardiovasc Surg 109 (1995) 1081-1089
15. Gramley F., Lorenzen J., Plisiene J., et al. Decreased plasminogen activator inhibitor and tissue metalloproteinase inhibitor expression may promote increased metalloproteinase activity with increasing duration of human atrial fibrillation. J Cardiovasc Electrophysiol 18 (2007) 1076-1082
16. Bender R., and Lange S. Adjusting for multiple testing-when and how?. J Clin Epidemiol 54 (2001) 343-349
17. Rowan R.A., and Billingham M.E. Pathologic changes in the long-term transplanted heart: a morphometric study of myocardial hypertrophy, vascularity, and fibrosis. Hum Pathol 21 (1990) 767-772
18. Shivalkar B., Van Loon J., Wieland W., et al. Variable effects of explosive or gradual increase of intracranial pressure on myocardial structure and function. Circulation 87 (1993) 230-239
19. Segel L.D., vonHaag D.W., Zhang J., et al. Selective overexpression of inflammatory molecules in hearts from brain-dead rats. J Heart Lung Transplant 21 (2002) 804-811
20. Mehra M.R., Uber P.A., Ventura H.O., et al. The impact of mode of donor brain death on cardiac allograft vasculopathy: an intravascular ultrasound study. J Am Coll Cardiol 43 (2004) 806-810
21. Chen Y., Liu Y., Yuan Z., et al. Rosiglitazone suppresses cyclosporin-induced chronic transplant dysfunction and prolongs survival of rat cardiac allografts. Transplantation 83 (2007) 1602-1610
22. McKoy R.C., Uretsky B.F., Kormos R., et al. Left ventricular hypertrophy in cyclosporine-induced systemic hypertension after cardiac transplantation. Am J Cardiol 62 (1988) 1140-1142
23. Aziz T.M., Burgess M.I., Haselton P.S., et al. Transforming growth factor beta and diastolic left ventricular dysfunction after heart transplantation: echocardiographic and histologic evidence. J Heart Lung Transplant 22 (2003) 663-673
24. Lijnen P.J., Petrov V.V., and Fagard R.H. Induction of cardiac fibrosis by transforming growth factor-beta(1). Mol Genet Metab 71 (2000) 418-435
25. Gramley F., Lorenzen J., Knackstedt C., et al. Age-related atrial fibrosis. Age 31 (2009) 27-38
26. Hao J., Wang B., Jones S.C., et al. Interaction between angiotensin II and Smad proteins in fibroblasts in failing heart and in vitro. Am J Physiol Heart Circ Physiol 279 (2000) H3020-H3030
27. Schultz Jel J., Witt S.A., Glascock B.J., et al. TGF-beta1 mediates the hypertrophic cardiomyocyte growth induced by angiotensin II. J Clin Invest 109 (2002) 787-796
28. Kertesz N.J., Gajarski R.J., Towbin J.A., et al. Effect of donor-recipient size mismatch on left ventricular remodeling after pediatric orthotopic heart transplantation. Am J Cardiol 76 (1995) 1167-1172
29. Mather P.J., Jeevanandam V., Eisen H.J., et al. Functional and morphologic adaptation of undersized donor hearts after heart transplantation. J Am Coll Cardiol 26 (1995) 737-742
30. Hosenpud J.D., Pantely G.A., Morton M.J., et al. Relation between recipient: donor body size match and hemodynamics three months after heart transplantation. J Heart Transplant 8 (1989) 241-243
31. Raichlin E., Villarraga H.R., Chandrasekaran K., et al. Cardiac allograft remodeling after heart transplantation is associated with increased graft vasculopathy and mortality. Am J Transplant 9 (2009) 132-139
32. Stetson S.J., Perez-Verdia A., Mazur W., et al. Cardiac hypertrophy after transplantation is associated with persistent expression of tumor necrosis factor-alpha. Circulation 104 (2001) 676-681
33. Lisy K., and Peet D.J. Turn me on: regulating HIF transcriptional activity. Cell Death Diff 15 (2008) 642-649
34. Ferrara N., Gerber H.P., and LeCouter J. The biology of VEGF and its receptors. Nat Med 9 (2003) 669-676
35. Natarajan R., Salloum F.N., Fisher B.J., et al. Hypoxia inducible factor-1 activation by prolyl 4-hydroxylase-2 gene silencing attenuates myocardial ischemia reperfusion injury. Circ Res 98 (2006) 133-140
36. Ginouves A., Ilc K., Macias N., et al. PHDs overactivation during chronic hypoxia "desensitizes" HIFalpha and protects cells from necrosis. Proc Natl Acad Sci USA 105 (2008) 4745-4750
37. Lario S., Mendes D., Bescos M., et al. Expression of transforming growth factor-beta1 and hypoxia-inducible factor-1alpha in an experimental model of kidney transplantation. Transplantation 75 (2003) 1647-1654
38. Nauck M., Karakiulakis G., Perruchoud A.P., et al. Corticosteroids inhibit the expression of the vascular endothelial growth factor gene in human vascular smooth muscle cells. Eur J Pharmacol 341 (1998) 309-315
39. Reinders M.E., Fang J.C., Wong W., et al. Expression patterns of vascular endothelial growth factor in human cardiac allografts: association with rejection. Transplantation 76 (2003) 224-230